Agilent Technologies Announces Expanded Use of Cancer Diagnostic in Europe
June 16 2017 - 5:00AM
Business Wire
PD-L1 IHC 28-8 pharmDx Will Give More Insight to Which
Patients with Urothelial Cancer are Most Likely to Benefit from
Opdivo (nivolumab)
Agilent Technologies Inc. (NYSE:A) today announced expanded
access to a clinically validated test for PD-L1 (programmed
death-ligand 1), that will help physicians in Europe make more
informed decisions about how best to treat patients with Urothelial
Cancer (UC).
Europe is the first region to launch a PD-L1 CE-IVD test for UC
globally. The CE marking demonstrates the product meets all
relevant European Medical Device Directives. The PD-L1 IHC
28-8 pharmDx has broad utility as it has already been previously CE
marked for detecting tumor cell PD-L1 expression for non-squamous,
non-small-cell lung cancer, squamous cell carcinoma of head and
neck and melanoma. PD-L1 IHC 28-8 pharmDx now has more clinically
validated tissue indications than any other commercially
manufactured PD-L1 assay on the market.
Opdivo (nivolumab), an immunotherapy developed by Bristol-Myers
Squibb, is indicated for the treatment of previously treated
locally advanced unresectable or metastatic UC in adults after
failure of prior platinum-containing therapy regardless of PD-L1
status. Data from a recent clinical study CA209275 (Checkmate 275),
showed that tumor PD-L1 expression assessed by PD-L1 IHC 28-8
pharmDx may help inform which UC patients are more likely to
respond to Opdivo.
Because individual patients may respond differently to the same
treatment, scientists have been focusing on the development of
personalized medicine, which is where Agilent's Dako brand of
diagnostics comes into play, providing important information about
the status of key biomarkers in individual cancer patients.
Agilent is a worldwide leader in partnering with pharmaceutical
companies to develop immunohistochemical-based diagnostics for
cancer therapy.
Expanded use in other countries is currently pending
approval.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A), is a global leader in
analytical laboratory technologies. With more than 50 years of
insight and innovation, our instruments, software, services,
solutions and people provide trusted answers to our customers' most
challenging questions. The company generated revenues of $4.20
billion in fiscal 2016 and employs about 13,000 people worldwide.
In 2012, Agilent acquired Dako, a well-known provider of reagents,
instruments, software and expertise to make accurate diagnoses and
determine the most effective treatment for cancer patients.
Information about Agilent is available here, and information about
Dako is available here.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170616005081/en/
Agilent TechnologiesVictoria Wadsworth-Hansen, +1 408-553-2005+
45 29336980victoria.wadsworth-hansen@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024